Over the past year, the waiting room at a Long Island plastic surgery office has been filling up in different ways. The rhinoplasties, eye lifts, and standard menu of cosmetic corrections that have defined the industry for decades are no longer the main reasons that patients come in. An increasing number of people are reporting specific complaints that were unnamed two years ago. They shed the pounds. They’re feeling better. They may have gone down four sizes. Then they noticed something unexpected when they looked in the mirror: a face that appeared older than they had remembered, with hollowed-out cheeks and a slight sagging where the skin used to sit tightly against a fuller structure underneath. They attained the body they desired, but in the process, their face grew older than they had intended.
This is the face of Ozempic. To put it simply, the aesthetic medicine sector is flourishing as a result. According to a survey conducted by the American Academy of Facial Plastic and Reconstructive Surgery, about 60% of facial plastic surgeons are reporting an increase in patients presenting with this particular condition. Over the past year, Dr. Lyle Leipziger, chief of plastic surgery at North Shore University Hospital and the Long Island Jewish Medical Center, has seen a 30% increase in his own practice. These patients are dealing with tissue sagging and facial volume loss associated with rapid weight loss. Although the link to GLP-1 medications isn’t always clear, anyone who has been observing the patient population change can clearly see the pattern.
| Category | Details |
|---|---|
| What Is “Ozempic Face” | A term describing facial sagging, hollowed cheeks, sunken eyes, and a gaunt, prematurely aged appearance caused by rapid fat loss in the face — a side effect of significant weight loss from GLP-1 drugs like Ozempic and Wegovy |
| Cause | Rapid weight loss depletes facial fat volume and causes descent of facial tissues; the faster the loss, the more pronounced the sagging — particularly in people over 50 |
| Surgeon Survey Finding | Approximately 60% of facial plastic surgeons reported seeing an increase in patients presenting with Ozempic face, per a survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) |
| Key Expert | Dr. Lyle Leipziger, Chief of Plastic Surgery at North Shore University Hospital and Long Island Jewish Medical Center — reported a 30% increase in patients with facial volume loss from rapid weight loss in his own practice over the past year |
| Hollywood Connection | Plastic surgeons and commentators have linked “Ozempic face” to dramatic appearance changes in numerous celebrities; John Goodman and Sharon Osbourne cited by surgeons — though both deny using weight-loss drugs |
| Compounding Aesthetic Issue | Buccal fat removal (surgical removal of cheek fat pads) combined with GLP-1-related fat loss is producing especially skeletal facial appearances on red carpets and film sets — raising questions about Hollywood’s beauty standards |
| Treatment Options | Dermal fillers, fat grafting, collagen-stimulating treatments, microneedling, and surgical facelifts — with cosmetic clinics reporting increased demand for volume-restoration procedures |
| Doctor’s Recommendation | Slowing the pace of weight loss to reduce facial volume depletion; patients newly on Ozempic advised to discuss a gradual weight-loss approach with their prescribing physician |
| Age Factor | Patients over 50 are disproportionately affected — facial fat loss is more visible and recovery of skin elasticity is slower with age; rapid loss at this stage accelerates apparent aging by years |
| Cultural Moment | The Guardian (March 2026) noted that Hollywood’s new aesthetic is producing public concern rather than aspiration — comment sections on celebrity photos now frequently read “she looks sick” rather than “she looks amazing” |
| Economic Angle | The cosmetic surgery and aesthetics industry is seeing a new category of demand directly tied to GLP-1 drug adoption — “Ozempic face reversal” is becoming its own clinical subspecialty |
Although the experience is startling, the biology is simple. Contrary to popular belief, fat is one of the things that keeps a face looking young, so when the body loses fat quickly, the face also loses it. The structural components that give a face its three-dimensional, lived-in appearance are the cheek pads, the soft fullness around the jaw, and the soft rounding beneath the eyes. When you swiftly remove them, what’s left is skin that has less to cling to and is slightly lowered, settling into previously absent lines and hollows. People over 50 are most affected because their skin elasticity has already started to deteriorate and their fat is less likely to redistribute in a positive way. On Ozempic, you can lose forty pounds in six months and feel victorious when you step on the scale. However, when you catch yourself in the bathroom light, you’ll feel something more complicated.
This story’s Hollywood aspect is where it becomes culturally intriguing and a little odd. Surgeons have been observing, with differing degrees of tact, that a number of well-known celebrities seem to be negotiating the unique aesthetic collision of GLP-1-driven fat loss and aggressive cosmetic procedures, such as buccal fat removal, fillers, and brow lifts, which are producing faces that look worked on in a way that has changed from aspirational to unsettling for many observers.
The comment sections beneath photos taken on the red carpet convey their own message, one that is more akin to concern than the traditional language of admiration and envy. “She looks sick.” “He looked so much better before.” In March 2026, The Guardian reported that Hollywood’s new look is causing “public ambivalence and even rejection,” pointing out that the combination of Ozempic-related fat loss and buccal fat removal is creating faces that appear nearly skeletal on screen.
The fact that buccal fat removal—the surgical hollowing of the cheeks that was popular a few years ago because sharp cheekbones were seen as a sign of elegance—now has an awkward relationship with GLP-1-induced facial thinning is particularly ironic. In certain instances, patients who underwent surgical fat removal and subsequently lost more facial volume due to drug-induced weight loss are getting a look that even their surgeons weren’t prepared for. At one body weight, the aesthetic calculation makes sense; at another, it does not.
The treatment menu for Ozempic faces is well-established for plastic surgeons and cosmetic dermatologists: microneedling, fat grafting, collagen-stimulating treatments, dermal fillers to restore lost volume, and, in more serious cases, surgical procedures to address tissue descent. A patient who has already made a financial investment in GLP-1 medications—Ozempic costs approximately $892 per month, while Wegovy costs $1,350—has shown a clear willingness to spend money on their appearance. Each of these represents revenue. This patient was not produced by the cosmetics industry. It was Novo Nordisk. However, the industry is undoubtedly prepared to accept them.
Here, a certain structural symmetry is difficult to ignore. When a medication intended to treat one health issue has a cosmetic side effect, it creates a new category of demand for a related industry that makes money in ways that no one at a diabetes medication company had anticipated. As this specific chain of events develops, it becomes less of an anomaly and more of a clear illustration of how the contemporary wellness economy functions: every solution comes with a new set of issues, and there is always someone who stands to gain from both.
